CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for Semaglutide Long-acting Injection from the U.S. Food and Drug Administration (FDA), according to a Monday Hong Kong bourse filing.
The indication for the approval is weight management in adults who are overweight or obese alongside a reduced-calorie diet and increased physical activity.